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ROsteoporosis Is a Major
Confounder in Observational
Studies Investigating
Bisphosphonate Therapy
in Aortic Stenosis
We read the paper “Do Bisphosphonates Slow the Progression of
Aortic Stenosis” by Aksoy et al. (1) with great interest. Given the
central role that calcification plays in the progression of aortic
stenosis, the question as to whether bisphosphonates might favor-
ably modify this disease process is an important one.
In their large retrospective study, the researchers found that there
was no difference in aortic stenosis progression between women who
were taking and not taking bisphosphonate therapy after a median
follow-up of 1.6 years. This lack of effect persisted even after
sophisticated propensity matching; however, we believe that this
analysis did not correct for one potentially important confounder.
The link between osteoporosis and increased vascular calcifica-
tion, the so-called calcification paradox, is well established, and the
researchers themselves previously extended this principle to aortic
valve calcification (2–4). We therefore believe that the presence of
osteoporosis in those prescribed bisphosphonate therapy may have
had a significant incremental effect on aortic stenosis progression.
As such, the lack of difference between the groups could be
interpreted as a sign that bisphosphonates were in fact successful in
normalizing disease progression in these patients.
In our opinion, it is unlikely that observational studies will be
able to disentangle the effects of bisphosphonates and osteoporosis
on aortic stenosis. The true impact of these drugs will only become
clear within the setting of a randomized controlled trial.
*Marc R. Dweck, MD, PhD
David E. Newby, MD, PhD
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Reply
We thank the correspondents for their interesting comment on our
recent paper (1). We would like to point out, however, that none
of the authors of the present paper have been associated with the
papers that they referenced. The calcification paradox whereby
vascular calcification is more prevalent in those with reduced bone
density or increased bone turnover has been well described.
Increased valvular calcification has also been described in patients
with osteoporosis, but specific data on whether osteoporosis
accelerates aortic stenosis progression has not to our knowledge
been reported. Additionally, we have no way of knowing whether
the elderly women in our study who did not receive bisphospho-
nates had some degree of osteoporosis. The fact that many were
receiving vitamin D and calcium supplementation suggests that a
proportion at least were considered at risk for osteoporosis. The
correspondents’ contention that bisphosphonates in our study may
have normalized an acceleration of aortic stenosis associated with
osteoporosis is therefore interesting but still hypothetical. We
agree with the correspondents and stated in our conclusions to the
paper that prospective clinical trials of specific bisphosphonates
will be needed to fully answer the question of the impact of this
class of drugs on aortic stenosis progression.
*Brian Griffin, MD
Olcay Aksoy, MD
*Department of Cardiovascular Medicine
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Challenging Interpretation of
Elevated Cardiac Troponin T
in a Complex Case
With Rhabdomyolysis
We read with interest the correspondence letter by Sribhen et al.
(1) referring to the article “Diseased skeletal muscle: a noncar-
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September 11, 2012:1027–30diac source of increased circulating concentrations of cardiac
troponin T” by Jaffe et al. (2) published in the October 2011
ssue of the Journal. In their letter, Sribhen et al. (1) share their
experience on a case of a 27-year-old man experiencing severe
rhabdomyolysis after abdominal surgery due to intestinal her-
niation with bowel gangrene. Initially, this patient showed a
concordant increase in the third-generation cardiac troponin T
(cTnT) and cTnI assays on the third post-operative day with a
consecutive fall in cTnT and cTnI levels. Subsequently, the
cTnI level decreased to reference ranges, whereas the cTnT
level began to rise again, reaching a maximum on the 18th
post-operative day. Based on the report of Jaffe et al. (2), the
esearchers argued that these findings support the hypothesis
hat the re-elevation of the cTnT level might be the conse-
uence of re-expression of cTnT isoforms in skeletal muscle
uring the subacute phase of rhabdomyolysis. In support of
heir hypothesis, the researchers argued that a higher rate of
levations in cTnT level as compared with cTnI level is also
ound in end-stage renal disease (3) and quoted reports on
ross-reactivity of the first-generation TnT assay (4).
In our view, this interpretation is neither substantiated by their
data nor the data provided by Jaffe et al. (2) in the original paper
or his comments accompanying this letter.
First, extensive testing during development of the cTnT assay
showed no false positive cTnT elevations, even in patients with
severe skeletal muscle injury and extremely high blood creatine
kinase activity.
Second, in the particular patient reported by Sribhen et al. (1),
here are many possible reasons for elevations in cTnT and cTnI
evels on the third post-operative day, such as post-operative
yocardial infarction, acute renal failure, systemic inflammatory
esponse syndrome due to intestinal gangrene, and pulmonary
mbolism, to name only a few. These established causes of
roponin release are—in our opinion—a much more likely expla-
ation for the cTnT elevations than re-expression of cTnT
soforms in skeletal muscle. There have been no scientific data yet
ndicating re-expression of cTnT in skeletal muscle in severely
iseased patients in the intensive care setting.
Third, the reasons for the discordant findings of cTnI and
TnT are unclear, and the limited clinical information provided
y Sribhen et al. (1) does not contribute to clarification. Several
actors may interfere with the cTnI measurements, causing a
alse negative result, such as hemolysis, heparin interference,
utoantibodies, heterophilic antibodies, and a lower analytical
ensitivity and precision of the third-generation cTnI versus
TnT assay (5).
The observation of cTnT, and less often cTnI, elevations in
ome patients with skeletal muscle myopathy or dystrophy is
nteresting and most likely explained by myocardial involvement
ue to a systemic disorder. Nevertheless, the possibility of
e-expression of cTnT in skeletal muscle merits thorough
cientific evaluation. However, the study cohort reported by
affe et al. (2), which is used in support of the case, is subject to
n inherent inclusion bias because only those patients who were
TnI negative but cTnT positive were included in the trial. So
ar, no data are available in an unselected population with
keletal muscle diseases. In their paper published in the Journal,
affe et al. (2) concluded that they found the “same molecular
eight proteins in diseased skeletal muscle and in the heart.”
owever, looking closer at the figures revealed that immuno-eactive proteins in the diseased skeletal muscle detected byWestern blotting had a different molecular weight as compared
with cTnT in heart muscle (Fig. 2 of their article). For the
soleus muscle extract, 2 peptides were heavily stained using the
monoclonal cTnT antibody M7, and these peptides had mo-
lecular weights much lower than cTnT (Fig. 3 of their article).
Interestingly, the skeletal muscle samples were not probed for
cTnI re-expression. Thus, it is impossible to prove the re-
expression of troponin T in skeletal muscle by these experiments.
Only sequencing of the proteins that were stained by the antibod-
ies in the Western blot would clarify if indeed a cTnT fragment or
much more likely unspecific binding of the antibodies in tissue
sections could explain the staining in the Western blot.
We believe that interpretation of elevated cTn concentrations,
particularly when more sensitive assays are used, has become a
challenging task for clinicians. However, the case by Sribhen et al.
(1) and the explanations provided by Jaffe et al. (2) are not
substantiated by robust scientific data and therefore will not aid in
explaining the TnT elevations in this complex case.
There is a large database indicating that elevation of cTns in the
absence of acute coronary syndrome, commonly mislabeled as a
false-positive cTn result, is an independent predictor of patient
outcome, particularly if myocardial damage is due to a different
mechanism than myocardial ischemia. Thus, so far there are no
robust scientific data supporting the hypothesis that re-expression
of cTnT in skeletal muscle may be a reasonable explanation for
elevated TnT levels in critical care.
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We thank Drs. Giannitis and Katus for their interest in our paper
(1) concerning the clinical specificity of cardiac troponin T (cTnT)
